{"entity":{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Pemetrexed, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Inhibrx Biosciences, Inc, now recruiting.","summary":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) is a phase 1/2 interventional study registered as NCT04198766 by Inhibrx Biosciences, Inc, with 340 participants planned, started 2019-12-10 and due to reach its primary completion in 2033-07. Interventions recorded: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04198766","url":"https://clinicaltrials.gov/study/NCT04198766"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","pemetrexed","gemcitabine"],"companies":["inhibrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04198766","phase":"1/2","setting":"An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Inhibrx Biosciences, Inc","enrolled":340,"outcomes":[]},"route":"/trials/nct04198766/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/"}]}}